pioneer target protein degrad novel
treatment modal initi buy pt
see ampl upsid platform pipelin
tremend potenti protein degrad novel therapeut
approach led emerg plethora compani
space highlight true platform play
advanc clinic program bullish view compani deriv
pipelin support power proteolysis-
target chimera protac platform devis industri leader
effici versabl platform help optim
avail asset also gener highly-differenti candid
long run among variou protein degrad startup arvina
compani advanc program clinic thu
far earli clinic safeti pk data two differ protac
two indic metastat castration-
resist prostat cancer mcrpc metastat breast cancer
mbc provid import poc support protac viabl
therapeut approach de-risk compani pipelin
program whole initi clinic data suggest drug
exposur lead program enter preclin efficaci
rang associ tumor growth inhibit suggest potenti
earli observ efficaci signal next data readout
mcprc mbc associ larg market opportun thu
initi efficaci data could value-inflect compani home
arsen earlier stage asset support balanc pipelin
strong follow-up program oncolog diversif
neurodegen diseas align sever
high-profil collabor includ genentech part roch rhhbi
rate rate bayer bayri rate
serv extern valid also gener
collabor revenu support in-hous program provid
downsid protect stock view note current
conserv assign valu mcrpc
mbc leav rest pipelin
program technolog platform free call option taken
togeth choos initi buy rate pt
definit distribut analyst rate analyst certif disclosur pleas refer page report
zoom protein degrad potenti transform therapeut approach attract target
protein degrad therapeut approach many-fold compar tradit small molecul inhibitor protein
degrad could target approxim undrugg protein dont kinas domain
inaccess activ site furthermor protein degrad act elimin undesir protein could appli
diseas protein mis-fold accumul root caus patholog process compar
gene therapi rnai technolog advantag target protein degrad also evid includ effici
develop manufactur process possibl systemic/brain exposur potenti oral bioavail well fewer
long-term toxic concern thu believ target protein degrad repres new treatment modal
potenti significantli broaden scope address target tackl challeng diseas come year
believ arvina platform strength may underappreci street among variou target protein degrad
technolog think protac differenti follow turn weak promiscu binder potent degrad
significantli expand number address protein target iter mechan allow usag low dosag
thu larger therapeut window enhanc select oral avail note three region protac
protein ligand linker ligas ligand play role specif potenc target degrad sinc protac
larger tradit small molecul therapeut convent optim paramet small molecul drug discoveri
readili appli develop protac-specif comput biolog biophys data rapid target
identif protac optim develop achiev desir featur relat potenc select deliver
versatil believ platform capabl evidenc demonstr high success rate
protac candid identif degrad protein target gener
protac capabl deliv multipl rout administr includ oral deliveri
abl penetr blood brain barrier wide rang protein class success target includ
nuclear protein transcript factor epigenet modul membran protein cytosol protein high molecular weight
initi clinic poc data de-risk protac franchis whole view develop innov
treatment approach two biggest question whether could safe drug-lik properti human
think initi data readout program provid favor answer question
de-risk compani pipelin platform whole safeti front drug well-toler
dose limit toxic dlt grade treatment relat advers event observ thu far pk front
daili oral administr drug accumul day day day drug exposur current dose
level surpass preclin efficaci exposur rang result expect
potenti efficaci signal may observ next data readout manag expect complet dose escal
program top-line data includ recist respons well pd/molecular data readout
meanwhil addit data updat program provid
market model assumpt model us commerci launch mcrpc project
new mcrpc patient current project launch price per year assum
yoy price growth peak penetr reach year assign probabl success
mcrpc base histor success rate phase studi favor view program
taken togeth assumpt yield probabl adjust world-wide revenu mcrpc
grow model us commerci launch breast cancer project
new patient among progress et current project launch
price per year assum yoy price growth peak penetr reach year
assign probabl success er mbc base histor success rate phase
studi favor view program taken togeth assumpt yield probabl adjust world-wide
revenu mbc grow
valuat risk reach price target current conserv assign valu
mcrpc mbc price target base equally-weight composit
multipl tax dilut ep discount back line
expect price-to-earnings multipl discount rate earli development-stag biotechnolog compani npv
share discount cash flow analysi use discount rate growth rate line expect discount
growth paramet earli development-stag biotechnolog compani risk achiev price target includ
regulatori commerci clinic develop manufactur financi liabil intellectu properti risk
tabl content
compani pipelin overview
ii thesi arvina
iv metastat castrate-resist prostat cancer mcrpc
 local advanc metastat breast cancer la/m bc
vi market model assumpt
vii valuat risk
clinical-stag biopharmaceut compani found new ct becam public septemb
compani dedic tackl debilit life-threaten diseas discoveri develop
commerci therapi degrad disease-caus protein
use proprietari technolog platform engin proteolysis-target chimera protac target protein degrad
design har bodi natur protein dispos system select effici degrad remov
protac technolog platform origin work perform yale univers scientif founder chief
compani current two clinical-stag program treatment patient metastat castrate-resist
prostat cancer mcrpc treatment patient local advanc metastat breast
current conserv
assign valu
er local advanc metastat
ii thesi arvina
thesi arvina
tremend potenti protein degrad new treatment modal target roughli undrugg protein
strong expertis develop protac degrad lead technolog prof craig crew lab yale
advanc clinic program emerg landscap protein degrad compani
earli clinic valid de-risk novel approach
proof concept poc clinic data mcrpc mbc program support protac platform viabl therapeut
modal de-risk compani protein degrad franchis whole
initi clinic data show favor safeti drug-lik properti
ar er well-character target mcrpc mbc respect success target may impli
rel straightforward clinic develop regulatori path
potenti valu inflect point near-term
mcrpc mbc associ larger market opportun initi efficaci data could value-inflect
drug exposur current dose level lead drug enter preclin efficaci rang associ tumor
growth inhibit suggest potenti earli observ clinic efficaci signal next data readout
strong follow-up oncolog pipelin extend expand beyond scope lead program
engin protac cross blood brain barrier penetr
thesi continu
collabor deal highli valid
partnership pharma may gener potenti mileston plu tier royalti
revenu gener support intern program provid down-sid protect
pro forma cash cash equival market secur septemb
expect fund
broad platform ip complement specif product ip
last year protac product patent portfolio includ issu us patent issu foreign patent
pend us patent applic pend foreign patent applic
without take potenti patent term extens account patent expir
expect time frame
proteolysis-target chimera protac har ubiquitin-
proteasom degrad disease-caus protein
figur protac function insid cell iter degrad target protein
protac
proteolysis-target chimera protac chimer modular small molecul engin induc protein degrad
ubiquitin-proteasom system one cell natur protein dispos system
protac compris three region protein ligand linker ligas ligand three region protac
degrad play role specif potenc target degrad
tabl protac combin advantag small molecul therapi gene-bas medicin
potenti treat
iter mechan
eas manufactur
figur area protac may
superior exist modal
protac degrad could significantli broaden scope
figur use alloster site target undrugg protein
protac bring versatil target undrugg protein across variou therapeut area
abil design weak bind protac initi rapid ubiquitin degrad target protein potenti
expand number disease-caus protein target includ protein address exist small
success deplet protein target
per manag expand ligas repertoir beyond vhl crbn iap includ tissue-
tumor-specif ligas target degrad allow protac platform potenti applic wide
rang therapeut area view
differenti featur protac protein degrad
figur iter mechan action well-
posit address target over-express
figur weak binder becom potent degrad
protac repeatedli induc ubiquitin
degrad protein thu protein degrad may
observ concentr much lower requir
typic small molecul inhibit
potenti low dose practic dose interv may
mitig toxic toler risk
pre-exist reservoir target protein
deplet protac need degrad newli
synthes may achiev even lower
tissu concentr potenti lead safeti benefit
flexibl dose regimen
weak promiscu binder becom potent degrad
protac requir high degre bind strength
target contrast small molecul inhibitor
requir strong bind target protein function
continu occupi protein activ site
provid opportun use protac technolog
repurpos small molecul weakli bind
target creat potent degrad
highlight follow differenti featur protac
figur mutat specif protac may engin
figur promiscu binder becom select degrad
ligand incorpor protac trimer complex
often caus ligand select increas thu degrad
profil protac even select bind profil
ligand alon
enhanc select protac contribut reduc
non-specif protein degrad subsequ toxic effect
possibl engin promiscu binder select
protein degrad also possibl target mutat protein
spare wild-typ protein figur
constantli enhanc abil predict degrad select
part core platform strength
develop protac capabl deliv
oral administr avoid risk advers event associ
intraven intramuscular administr potenti
infect blood clot infus site
oral deliveri offer competit advantag therapeut
approach gene-bas medicin offer
conveni potenti lower price tag
protac platform support hit identif candid
figur protac platform includ proprietari synthet protac matrix combin comput biolog
biophys data allow rapid identif optim effici protein degrad
approach engin three compon
protac compris three region protein ligand linker ligas ligand three region protac degrad play
role specif potenc target degrad
de novo ligand discov high-throughput screen biophys direct bind approach virtual silico computer-bas
screen affinity-bas hit identif dna-encod librari
also select ligand known bind protein target may limit lack potenc function metabol
instabl off-target effect
current util group wide express ligas select ligand proprietari librari ligas incorpor
protac
platform expans effort research addit ligas express specif tissu diseas identifi
discov associ bind ligand offer differ select profil could advanc protac technolog
linker select critic rapid identif protein degrad introduc function select nonfunct
nonselect bind ligand upon incorpor protac molecul
linker composit also use modul properti protac membran permeabl aqueou solubl metabol
stabil biodistribut
current select proprietari librari linker engin particular length flexibl composit enabl
effici format trimer complex essenti ubiquitin transfer protein degrad
underappreci street
protac larger tradit small molecul therapeut thu convent optim paramet small molecul
drug discoveri readili appli develop protac-specif comput biolog biophys data
identif optim protac
systemat approach scientif know-how allow compani rapidli progress target identif protac
optim develop make protac properti suffici drive potent effect tumor cell
protein degrad protac platform possess desir featur includ tunabl properti relat potenc select
deliver versatil
power protac platform demonstr
gener protac capabl deliv multipl rout administr includ oral deliveri abl
penetr blood brain barrier
demonstr high success rate protac candid identif degrad protein
wide rang protein class success target includ nuclear protein transcript factor epigenet modul
membran protein cytosol protein high molecular weight neuroprotein aggreg
partnership may gener potenti mileston plu tier royalti
genentech part roch rhhbi rate septemb expand novemb
discoveri deal up-front develop commerci mileston aggreg payment excess tier
manag joint research committe joint project team compos repres genentech
genentech final decision-mak author
rate decemb
discoveri deal up-front develop commerci mileston aggreg payment tier royalti
collabor manag joint research committe compos equal number repres
final decision-mak author
bayer bayri rate june
pharmaceut collabor direct equiti invest focus gynecolog oncolog cardiovascular diseas target
up-front commit fund exce includ equiti invest potenti mileston payment plu
launch oerth agriculture-focus joint ventur commit fund bayer bayer arvina share
ownership govern oerth equal
look industri landscap protein degrad
tabl preclin stage compani focus protein degrad privat
gsk gsk rate
platform either inhibit har ligas explor least
gilead rate
celgen celg rate
daedalu platform predict model synthet chemic
usmit technolog util untap ubiquitin ligas cullin
novel binders/link hard-to-target factor tissue-restrict
differ small molecul mircroarray screen cell lysat
protein homeostat modul novel small molecul
allow cell-bas assay modifi ligas interact surfac
influenc substrat degrad
chemoproteom innov approach chemic interrog
protein live system discov pharmacolog target
new bind pocket hotspot protein
addit start-up compani sever larg pharmaceut compani disclos preclin invest protein degrad
includ rate astrazeneca azn rate novarti nv rate
iv mcrpc
overview potenti first-in-class
protac protein degrad design select target degrad androgen receptor ar
orally-bioavail brain penetr
high potenc vcap cell degrad ar multipl cell line
highli select ar hour treatment vcap cell vitro ar degrad protein
rapid ar degrad near-maxim degrad within hour administr vitro
demonstr promis preclin anti-tumor activ
inhibit vcap prolifer potent enzalutamid
shown antitumor activ preclin model ar mutat overexpress common mechan resist
shown abil treat enzalutamide-resist insensit cancer mous model
develop potenti treatment mcrpc progress standard care soc either enzalutamid
program receiv track design fda may
phase trial initi
initi data report octob demonstr favor in-human safeti pk/pd profil see next slide
previous nonsteroid select androgen receptor degrad sard astrazeneca azn rate develop
shown downregul ar despit promis phase data develop discontinu due toler
issu much improv safeti profil pois first-in-class ar degrad view
drug concentr result protein degrad
figur differ stage prostat cancer treatment option
pca mcrpc
malign new case year us
second lead caus cancer-rel death male
world
androgen-depriv therapi primari therapi
late-stag dissemin pca includ surgic
reduc
advanc pca patient progress
major
factor contribut pca-rel death estim
men us live
patient metastat diseas diagnosi
year patient
diagnos mcrpc five-year surviv mcrpc
despit improv increas treatment
new agent treatment combin prostat cancer
tabl current therapeut approach prostat cancer
current treatment mcrpc inadequ
patient mcrpc develop resist treatment least one androgen receptor signal inhibitor arsi
patient mcrpc respond first-lin treatment either abirateron acet zytiga janssen biotech
privat enzalutamid xtandi rate
treatment first-lin arsi lead month progression-fre surviv
resist mechan ar inhibitor includ
recurr mutat ar enhanc patient
overexpress circul ar splice constitut activ version ar
longer inhibit ar inhibitor marker aggress mcrpc
resist patient level rise suggest ar remain princip driver diseas need develop new ar-
target agent address resist mechan
patient mcrpc diseas progress treatment second-gener ar inhibitor may treat either
chemotherapi differ second-gener ar inhibitor depend patient fit level
patient respond second-lin treatment differ ar inhibitor
respons achiev typic less half durabl month progression-fre surviv
treatment progress second ar inhibitor chemotherapi patient mcrpc limit treatment option
pain manag palli care option
closer look arsi treat mcrpc
mechan action
abirateron inhibit residu androgen biosynthesi androgen depriv therapi
enzalutamid second-gener nonsteroid ar inhibitor affect ar pathway three way
bind ar greater rel affin bicalutamid reduc effici ar nuclear transloc
impair dna bind androgen respons element
recruit coactiv
mcrpc pre-doc mild/no symptom viscer met
mcrpc pre-doc mild/no symptom viscer met
tabl clinic trial demonstr surviv advantag mcrpc
mcrpc symptomat
mcrpc pre-doc mild/no symptom viscer met
doubl time month
mcrpc post- unfit
arsi resist insensit tumor model
figur tumor growth inhibit
figur tumor growth inhibit
may like use arsi chemotherapi
figur treatment continuum prostat cancer
olaparib
atm
apalutamid
modifi osanto leiden eau neal shore md urology- gold journal
phase initi data readout suggest safeti drug-lik
properti human
phase dose level enter
patient treat first three dose cohort current enrol fourth cohort qd
dose-proport increas exposur dose cohort enter preclin efficaci exposur rang
drug accumul occur day day day tmax hour day
dose limit toxic dlt observ grade treatment relat observ
top-line data includ recist respons well pd/molecular data complet dose escal
dose expans develop next-gener ar
plan dose expans upon identif
accord file identif recommend phase dose on-going phase studi
plan enrol addit patient mcrpc expans cohort data collect patient expans cohort
expect analyz base pre- post-chemotherapi post-enzalutamid post-abirateron post-
enzalutamid post-abirateron presenc absenc ar splice variant ar mutat ar amplif
addit believ favor safeti potenti observ meaning clinic activ may allow expans
earlier line treatment current least one prior arsi combin arsi
develop plan next-gener ar degrad
exampl point mutat ligand-bind domain ar result activ ar glucocorticoid
caus resist standard care regimen
degrad ar splice
shown correl lack respons current soc mcrpc
truncat form ar lack ligand-bind domain necessari bind
thu signal dimer vs heterodim would unaffect
current explor develop protac degrad directli well ar splice variant
anoth promis candid mcrpc
endocyt acquir novarti nv rate radiolabel small molecul bind
high affin prostate-specif membran antigen psma enabl beta particl therapi target mcrpc
single-arm single-cent phase trial evalu heavili pre-treat patient popul receiv line
prior chemotherapi docetaxel cabazitaxel receiv prior abirateron acet and/or enzalutamid
reduct least baselin patient
reduct least baselin patient
reduct patient identifi except respond
median month median overal surviv os month observ
notabl patient respons median month median os month compar
month median os month achiev respons
patient prostat cancer work group recist evalu nodal viscer target lesion
follow ct scan baselin confirm object respons seen patient includ
complet partial respons rate respect
well toler signific dose-limit toxic observ
common treatment-rel toxic grade xerostomia dri mouth seen patient higher
previous report gener didnt requir intervent
occurr treatment-rel grade hematolog toxic low compar largest retrospect
 er mbc
overview potent select estrogen receptor
protac protein degrad design specif target degrad estrogen receptor er
high potenc demonstr er reduct vitro studi
previous show compel anti-tumor activ preclin studi
demonstr near-complet er degrad tumor cell induc robust tumor shrinkag dose singl
agent multipl er-driven xenograft model
show superior anti-tumor activ singl agent combin inhibitor compar soc agent
fulvestr singl agent combin inhibitor
current develop er local advanc metastat breast cancer la/mbc patient
phase trial initi assess safeti toler pk
data would also includ measur anti-tumor activ pd readout secondari endpoint
initi data studi releas octob demonstr favor safeti pk profil
given improv efficaci fulvestr synergi inhibitor observ preclin studi phase
trial combin inhibitor plan on-going phase studi
current treatment er posit metastat breast cancer
closer look er posit breast cancer
breast cancer bc second common
cancer women women expect
diagnos invas bc us
newli diagnos breast cancer er
posit mbc account newli
despit avail newer endocrin
therapi et target agent mani patient
develop resist treatment
although mechan underli endocrin
resist complex studi suggest
major patient resist diseas er
remain engag continu contribut
diseas pathogenesi suggest er
remain viabl target resist tumor
addit activ mutat estrogen-
bind domain gene encod er
found mediat resist
suggest need develop effect er
closer look fulvestr
fulvestr astrazeneca fda-approv select
estrogen receptor degrad serd er posit mbc
progress tamoxifen therapi
fulvestr use monotherapi combin
inhibitor palbociclib inhibitor alpelisib
addit alkylsulphinyl moieti endogen er
ligand led develop fulvestr
fulvestr bind er induc structur chang lead
increas surfac hydrophob subsequ degrad
er
fulvestrant-induc degrad affect ligand-independ
function er readili address tamoxifen
like less risk endometri cancer tamoxifen due
howev fulvestr highli insolu compound poor
oral bioavail also short intraven half-lif poor
system exposur month fulvestr treatment
er baselin level remain
taken togeth believ fulvestr provid poc er
degrad bc howev limit clinic success call
develop effect serd
preclin data suggest superior fulvestr
tumor inhibit
figur effect
fulvestr tumor inhibit pdx model
figur palbociclib effect
fulvestr palbociclib mous xenograft model
phase initi data readout suggest safeti drug-lik
properti human
phase dose level enter
patient treat first dose cohort current enrol second cohort qd
drug accumul occur day day day tmax hour hour
dose limit toxic dlt observ grade treatment relat observ
addit trial updat plan
sever serd develop competitor
tabl competit serd current develop breast cancer
novarti nv rate
rate
vi market model assumpt
model us commerci launch mcrpc project new mcrpc patient current
project launch price per year assum yoy price growth peak penetr
reach year assign probabl success mcrpc base histor success rate phase
studi favor view program taken togeth assumpt yield probabl adjust world-wide
revenu mcrpc grow
model us commerci launch breast cancer project new patient
among progress et current project launch price per year
assum yoy price growth peak penetr reach year assign probabl success arv-
er mbc base histor success rate phase studi favor view program taken
togeth assumpt yield probabl adjust world-wide revenu mbc grow
current conserv assign valu mcrpc mbc price target
base equally-weight composit multipl tax dilut ep
discount back line expect price-to-earnings multipl discount rate earli development-stag
biotechnolog compani npv discount cash flow analysi use discount rate
growth rate line expect discount growth paramet earli development-stag biotechnolog compani risk
achiev price target includ regulatori commerci clinic develop manufactur financi liabil intellectu
regulatori risk regulatori risk could receiv regulatori approv product
develop regulatori approv may delay applic submit addit healthcar reform
commerci risk commerci risk success market sell
pipelin product receiv regulatori approv current compani market product need build sale
market medic liaison team well establish distribut infrastructur risk includ physician accept drug
govern payor reimburs line expect potenti government price control
clinic develop risk develop risk associ preclin clinic studi potenti delay start
trial current investig sever asset clinic trial enrol may take signific amount time clinic trial
trial may postpon delay varieti reason addit outcom trial difficult predict could fail
number reason includ safeti efficaci
manufactur risk oper manufactur facil third-parti contract manufactur reli
manufactur agreement need implement commerci product manufactur capac demand
other expect increas develop commerci could face issu time cost present
risk well abil manufactur consist product manufactur facil highli regul subject risk
closur delay
continu next slide
financi risk incur oper loss sinc incept view may achiev profit sever year
compani could need rais capit futur sustain oper addit stock biotechnolog compani like publicli trade
compani subject market volatil liquid risk small trade float
liabil risk product candid may caus undesir side effect properti could result legal action taken
subject trial commerci patient compani product liabil lawsuit common biopharmaceut industri
compani also vulner typic busi liabil associ conduct busi litigi environ
intellectu properti risk reli patent trade secret protect product competit biotechnolog industri
litigi lawsuit consid normal part busi court might uphold intellectu properti right though
far could find infring upon anoth parti properti right addit biotech firm could potenti find loophol
intellectu properti estat might enabl launch gener version product prior expir patent
protect product unabl obtain protect intellectu properti right may abl compet effect
commerci market
figur thousand dollar except per share item
research develop
gener administr
loss oper
total incom
chang fair valu prefer unit warrant
loss equiti method invest
loss incom tax
benefit incom tax
chang fair valu redeem convert prefer stock unit
net loss attribut common share unit
except patient number specifi
progress line
penetr elig patient
number patient receiv
annual cost
us new mcrpc case
launch time us
us yoy growth new case
us yoy growth price
time peak year
probabl success
compani report bloomberg nation cancer institut nation institut wainwright estim
except patient number specifi
progress endocrin therapi et
penetr elig patient
number patient receiv
annual cost
launch time us
us yoy growth new case
us yoy growth price
time peak year
probabl success
compani report bloomberg nation cancer institut nation institut wainwright estim
discount
sensit ep estim
discount
chang work capit
rate a- chang net work capit capital-expenditure
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc arvn-u
rate price target histori inc biib-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein alicia yin ph matthew caufield certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur inc
inc vertex pharmaceut inc includ without limit option right warrant futur long short
novemb neither firm affili benefici class common equiti secur
inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc inc
invest bank servic within twelv month seek compens compani mention
report invest bank servic within three month follow public research report
firm make market inc inc inc date research
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
